Invitrogen™ CD18 (LFA-1 beta) Monoclonal Antibody (M18/2), FITC, eBioscience™, Invitrogen™

Beschreibung

Description: The M18/2 monoclonal antibody reacts with mouse CD18, the 90-95 kDa integrin beta 2 glycoprotein. CD18 is the common beta subunit that non-covalently associates with CD11a (alpha L), CD11b (alpha M) and CD11c (alpha X) to form LFA-1, Mac-1 and gp150/95. Heterodimers of CD18 and the a subunits are expressed broadly by all leukocytes with NK and T cells showing higher density of surface expression. Through the interactions of LFA-1, Mac-1 and gp150/95 with their counter-receptors, CD18 is involved in cellular adhesion and the immune response. Applications Reported: The M18/2 antibody has been reported for use in flow cytometric analysis. Applications Tested: The M18/2 antibody has been tested by flow cytometric analysis of mouse splenocytes and bone marrow cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser. Filtration: 0.2 μm post-manufacturing filtered.

CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes. CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling. CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis. Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1). Two transcript variants encoding the CD18 protein have been identified.